Skip to main content

Proceeding contribution from James Brokenshire (Conservative) in the House of Commons on Thursday, 9 September 2010. It occurred during Adjournment debate on Controls on Legal Highs.


Controls on Legal Highs

The relevant point here concerning legal highs is that the ACMD flagged up to the Government its concern about mephedrone, pointing out that there was a problem it needed to do further work on to reach a final conclusion. It was so concerned that it was almost advising the Government to take preventive steps. Through this mechanism we want to be able to act, from a public harm and a warning perspective, to ensure that those issues are dealt with swiftly and quickly. In other words, we want to try to reduce the risk of harm occurring. That is the emphasis and intention behind the temporary banning power, and it is consistent with the approach taken in other legislation: that if the law is subsequently changed, pre-existing offences that may have been incurred still subsist. I should like to mention Ivory Wave, which is causing a number of hon. Members significant concern and has been mentioned in the press and the media. I want to deal with certain reports associating the use of the so-called legal high-branded product Ivory Wave with a number of localised accident and emergency presentations in the last few weeks. Health alerts have been issued by the chief medical officers for England and Wales and Scotland, and the FRANK service was updated to highlight the risks that we are presently aware of that are associated with Ivory Wave. We are actively monitoring the situation. My Department has received early information from the Scottish Crime and Drugs Enforcement Agency that the latest Ivory Wave products associated with the admissions in Lothian may contain a non-controlled amphetamine-type stimulant, Desoxypipradrol, or 2-DPMP. Confirmation from forensic providers and details of other sampling is awaited. In Edinburgh, Lothian and Borders police, in partnership with the City of Edinburgh public health authorities, have visited a number of ““head”” shops, which has led to the removal of Ivory Wave products from sale. Hampshire police have also conducted a joint operation with trading standards, raiding two head shops on the Isle of Wight, resulting in the seizure of large quantities of legal highs and the arrest of two individuals for suspected supply of controlled drugs. In light of that information, earlier this week I spoke to the chair of ACMD, Professor Les Iversen, and asked the council to keep a close interest in developments here and provide advice as necessary. I have instructed my officials to share with the ACMD information that we have and provide regular updates. There were previous indications that the so-called legal high Ivory Wave had contained certain controlled drugs. Different supplies of Ivory Wave using that brand name contain different drugs, some of which may already be controlled drugs, hence our seeking further information on the forensics and the nature of the drugs seized under that branding. We are dealing with this emerging and dynamic problem of legal highs, including BZP, synthetic cannabinoids, mephedrone and the latest so-called legal high. Although effective legislation is integral to our response to protect the public—particularly the health of our young people—from the harms of the drugs, there is no easy fix. We are working closely with the ACMD out of a shared concern about these new psychoactive substances. As well as advice on individual drugs, our response will also be informed by the advisory council's thematic work on legal highs. That response must be wide-ranging, encompassing all the strands that will reduce both demand and supply. But let me say clearly to anyone tempted to try a legal high that just because something is advertised as legal does not mean it is safe—and it may not even be legal.


Secondary information

Type
Proceeding contribution
Reference
515 c154-5WH 
Session
2010-12
Chamber / Committee
Westminster Hall
Subjects
Drugs Misuse Mephedrone
Link
View this Proceeding contribution on www.publications.parliament.uk